https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-27 / Ann Surg Oncol 2021 Oct;28(11):6126-6137
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-27 / Ann Surg Oncol 2021 Oct;28(11):6126-61372021-02-27 00:00:002021-02-27 00:00:00A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-26 / Ann Surg Oncol 2021 10;28(11):6138-6139
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-26 / Ann Surg Oncol 2021 10;28(11):6138-61392021-02-26 00:00:002021-02-26 00:00:00ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-25 / Front Oncol 2021;11:590764
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-25 / Front Oncol 2021;11:5907642021-02-25 00:00:002021-02-25 00:00:00Modulated Electro-Hyperthermia Facilitates NK-Cell Infiltration and Growth Arrest of Human A2058 Melanoma in a Xenograft Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-21 / J Transl Med 2020 04;18(1):176
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-21 / J Transl Med 2020 04;18(1):1762020-04-21 00:00:002021-05-19 12:39:42Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-772020-02-21 00:00:002020-02-21 00:00:00[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / J Immunother Cancer 2020 02;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-31 / Biomed. Pharmacother. 2020 May;125:1099662020-01-31 00:00:002020-01-31 00:00:00Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-4882020-01-24 00:00:002020-01-24 00:00:00Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-7552019-11-15 00:00:002019-11-15 00:00:00Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-11 / Biomedicines 2019 Oct;7(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-11 / Biomedicines 2019 Oct;7(4)2019-10-11 00:00:002021-05-19 12:40:37Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
